LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 1 | J24 | 72 | hr | 1401 | 2520 | 4223 | 0.5967 | 0.3964 |
SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 2 | J24 | 72 | hr | 1401 | 2494 | 4223 | 0.5906 | 0.3872 |
SK-BR-3 | WZ-4-145 | 0.04 | uM | LJP6 | 3 | J24 | 72 | hr | 1401 | 2313 | 4223 | 0.5477 | 0.3230 |
SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 1 | M12 | 72 | hr | 1401 | 1674 | 4223 | 0.3964 | 0.0966 |
SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 2 | M12 | 72 | hr | 1401 | 1721 | 4223 | 0.4075 | 0.1132 |
SK-BR-3 | XMD16-144 | 0.04 | uM | LJP5 | 3 | M12 | 72 | hr | 1401 | 1490 | 4223 | 0.3528 | 0.0314 |
SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 1 | P18 | 72 | hr | 1401 | 3572 | 4223 | 0.8458 | 0.7693 |
SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 2 | P18 | 72 | hr | 1401 | 4182 | 4223 | 0.9903 | 0.9854 |
SK-BR-3 | Brivanib | 0.04 | uM | LJP5 | 3 | P18 | 72 | hr | 1401 | 4777 | 4223 | 1.1312 | 1.1963 |
SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 1 | H06 | 72 | hr | 1401 | 3430 | 4223 | 0.8122 | 0.7189 |
SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 2 | H06 | 72 | hr | 1401 | 3897 | 4223 | 0.9228 | 0.8844 |
SK-BR-3 | Buparlisib | 0.04 | uM | LJP5 | 3 | H06 | 72 | hr | 1401 | 3564 | 4223 | 0.8439 | 0.7664 |
SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 1 | L24 | 72 | hr | 1401 | 3520 | 4223 | 0.8335 | 0.7508 |
SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 2 | L24 | 72 | hr | 1401 | 3546 | 4223 | 0.8397 | 0.7600 |
SK-BR-3 | BX-912 | 0.04 | uM | LJP5 | 3 | L24 | 72 | hr | 1401 | 3733 | 4223 | 0.8840 | 0.8263 |
SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 1 | H12 | 72 | hr | 1401 | 1883 | 4223 | 0.4459 | 0.1706 |
SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 2 | H12 | 72 | hr | 1401 | 1782 | 4223 | 0.4220 | 0.1349 |
SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 3 | H12 | 72 | hr | 1401 | 1990 | 4223 | 0.4712 | 0.2086 |
SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 1 | G12 | 72 | hr | 1401 | 3375 | 4223 | 0.7992 | 0.6994 |
SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 2 | G12 | 72 | hr | 1401 | 3171 | 4223 | 0.7509 | 0.6271 |
SK-BR-3 | Celastrol | 0.04 | uM | LJP6 | 3 | G12 | 72 | hr | 1401 | 3133 | 4223 | 0.7419 | 0.6137 |
SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 1 | F06 | 72 | hr | 1401 | 4460 | 4223 | 1.0561 | 1.0840 |
SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 2 | F06 | 72 | hr | 1401 | 4219 | 4223 | 0.9990 | 0.9986 |
SK-BR-3 | CGP60474 | 0.04 | uM | LJP5 | 3 | F06 | 72 | hr | 1401 | 4677 | 4223 | 1.1075 | 1.1609 |
SK-BR-3 | CGP60474 | 0.04 | uM | LJP6 | 1 | G06 | 72 | hr | 1401 | 1008 | 4223 | 0.2387 | -0.1395 |